Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Intensity Therapeutics Inc (NASDAQ: INTS) closed the day trading at $0.27 down -1.93% from the previous closing price of $0.28. In other words, the price has decreased by -$1.93 from its previous closing price. On the day, 1.98 million shares were traded. INTS stock price reached its highest trading level at $0.2837 during the session, while it also had its lowest trading level at $0.265.
Ratios:
For a better understanding of INTS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.40 and its Current Ratio is at 1.40. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INTS now has a Market Capitalization of 12691461 and an Enterprise Value of 10600469.
Stock Price History:
The Beta on a monthly basis for INTS is 3.73, which has changed by -0.9369159 over the last 52 weeks, in comparison to a change of 0.1716845 over the same period for the S&P500. Over the past 52 weeks, INTS has reached a high of $4.35, while it has fallen to a 52-week low of $0.19. The 50-Day Moving Average of the stock is -10.33%, while the 200-Day Moving Average is calculated to be -80.68%.
Shares Statistics:
Over the past 3-months, INTS traded about 4.19M shares per day on average, while over the past 10 days, INTS traded about 3960480 shares per day. A total of 47.06M shares are outstanding, with a floating share count of 40.09M. Insiders hold about 14.80% of the company’s shares, while institutions hold 4.20% stake in the company. Shares short for INTS as of 1755216000 were 987865 with a Short Ratio of 0.24, compared to 1752537600 on 387444. Therefore, it implies a Short% of Shares Outstanding of 987865 and a Short% of Float of 2.3699999.
Earnings Estimates
A detailed examination of Intensity Therapeutics Inc (INTS) is currently in progress, with 2 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.35 and -$0.38 for the fiscal current year, implying an average EPS of -$0.37. EPS for the following year is -$0.37, with 2.0 analysts recommending between -$0.24 and -$0.5.
